NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD
Neoleukin Therapeutics, Inc. (NLTX) has a consensus analyst rating of Hold, based on 14 analysts covering the stock. Of those, 5 recommend buying, 8 recommend holding, and 1 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
